Neurologic complications secondary to cerebrovascular damage are prevalent in children with
sickle cell disease. These patients experience both clinically overt cerebrovascular
accidents and "silent infarctions" demonstrated by magnetic resonance imaging (MRI). They are
also at risk for neurocognitive abnormalities.We hypothesize that daily, low-dose aspirin
therapy will safely diminish the incidence and progression of cognitive deficits as well as
the predisposition to overt and silent stroke in children with homozygous sickle cell disease
(Hgb SS) or hemoglobin S Beta Zero Thalassemia (Hgb SB-0 Thal). In order to optimize the
design of a future trial to test this hypothesis, we propose a pilot study to test the safety
and tolerability of aspirin in young children with sickle cell disease.
Phase:
Phase 1
Details
Lead Sponsor:
University of Rochester
Collaborators:
Bayer National Institute of Neurological Disorders and Stroke (NINDS) University of Miami